Acceleron Pharma Inc (XLRN):企業の財務・戦略的SWOT分析

◆英語タイトル:Acceleron Pharma Inc (XLRN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH131003FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年3月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Acceleron Pharma Inc (XLRN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Acceleron Pharma Inc (Acceleron) is a clinical stage biopharmaceutical company that discovers, develops and commercializes drugs to treat serious and rare diseases. Reblozyl is the company’s only commercial product used for the treatment of transfusion-dependent anemia patients with beta thalassemia and myelodysplastic syndromes (MDS). The company’s lead therapeutic candidate, luspatercept-aamt is in trials for the treatment of anemia and associated complications in myelodysplastic syndromes, and myelofibrosis. Its other pipeline products are being evaluated for the treatment of lung disease. The company has operations in the US, Bermuda and Switzerland. Acceleron Pharma is headquartered in Cambridge, Massachusetts, the US.

Acceleron Pharma Inc Key Recent Developments

Feb 25,2021: Acceleron reports fourth quarter and full year 2020 financial results
Feb 17,2021: Acceleron to Webcast Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
Nov 05,2020: Acceleron announces third quarter 2020 REBLOZYL net sales
Nov 05,2020: Acceleron reports third quarter 2020 operating and financial results
Sep 16,2020: Acceleron appoints Laura J. Hamill to its Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Acceleron Pharma Inc – Key Facts
Acceleron Pharma Inc – Key Employees
Acceleron Pharma Inc – Key Employee Biographies
Acceleron Pharma Inc – Major Products and Services
Acceleron Pharma Inc – History
Acceleron Pharma Inc – Company Statement
Acceleron Pharma Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Acceleron Pharma Inc – Business Description
Acceleron Pharma Inc – Corporate Strategy
Acceleron Pharma Inc – SWOT Analysis
SWOT Analysis – Overview
Acceleron Pharma Inc – Strengths
Acceleron Pharma Inc – Weaknesses
Acceleron Pharma Inc – Opportunities
Acceleron Pharma Inc – Threats
Acceleron Pharma Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Acceleron Pharma Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 25, 2021: Acceleron reports fourth quarter and full year 2020 financial results
Feb 17, 2021: Acceleron to Webcast Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
Nov 05, 2020: Acceleron announces third quarter 2020 REBLOZYL net sales
Nov 05, 2020: Acceleron reports third quarter 2020 operating and financial results
Sep 16, 2020: Acceleron appoints Laura J. Hamill to its Board of Directors
Aug 06, 2020: Acceleron announces second quarter 2020 REBLOZYL Net Sales
Aug 06, 2020: Acceleron reports second quarter 2020 operating and financial results
Jun 04, 2020: Acceleron appoints Christopher Hite to its board of directors
Jun 04, 2020: Acceleron Pharma: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers
May 11, 2020: Acceleron reports first quarter 2020 operating and financial results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Acceleron Pharma Inc, Key Facts
Acceleron Pharma Inc, Key Employees
Acceleron Pharma Inc, Key Employee Biographies
Acceleron Pharma Inc, Major Products and Services
Acceleron Pharma Inc, History
Acceleron Pharma Inc, Subsidiaries
Acceleron Pharma Inc, Key Competitors
Acceleron Pharma Inc, Ratios based on current share price
Acceleron Pharma Inc, Annual Ratios
Acceleron Pharma Inc, Annual Ratios (Cont...1)
Acceleron Pharma Inc, Interim Ratios
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Acceleron Pharma Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Acceleron Pharma Inc (XLRN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Freudenberg & Co KG:企業の戦略的SWOT分析
    Freudenberg & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Dowa Holdings Co., Ltd.:戦略・SWOT・企業財務分析
    Dowa Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Dowa Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Mitsubishi Estate Co., Ltd. (8802):企業の財務・戦略的SWOT分析
    Mitsubishi Estate Co., Ltd. (8802) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Loral Space & Communications Inc. (LORL):企業の財務・戦略的SWOT分析
    Loral Space & Communications Inc. (LORL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Nippon Flour Mills Co., Ltd.:企業の戦略・SWOT・財務分析
    Nippon Flour Mills Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nippon Flour Mills Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • HollyFrontier Corporation (HFC)-石油・ガス分野:企業M&A・提携分析
    Summary HollyFrontier Corporation (HollyFrontier) is an independent energy company. It carries out crude oil refining and wholesale marketing of refined petroleum products. The company produces and markets high-value light products such as gasoline, diesel, jet fuel, specialty lubricant products, he …
  • Eesti Energia AS:戦略・SWOT・企業財務分析
    Eesti Energia AS - Strategy, SWOT and Corporate Finance Report Summary Eesti Energia AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Walchandnagar Industries Ltd
    Walchandnagar Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Walchandnagar Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Conversant Intellectual Property Management Inc.:企業のM&A・事業提携・投資動向
    Conversant Intellectual Property Management Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Conversant Intellectual Property Management Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business descri …
  • PhoenixBio Co Ltd (6190):製薬・医療:M&Aディール及び事業提携情報
    Summary PhoenixBio Co Ltd (PhoenixBio) is a life science company that offers medical therapy solutions. The company offers contract study services including dosing of test-compounds, sampling, in-life phase trials, chemical analysis, measurement of human albumin levels, and metabolic enzymes and blo …
  • TransAlta Renewables Inc (RNW):電力:M&Aディール及び事業提携情報
    Summary TransAlta Renewables Inc (TransAlta Renewables), a subsidiary of TransAlta Corp, is a renewable energy company that operates and develops hydropower, wind power, and gas power generation facilities. The company develops, owns, operates, and maintains a fleet of power generation assets in Can …
  • Eneco Holding NV-エネルギー分野:企業M&A・提携分析
    Summary Eneco Holding N.V. (Eneco) is an integrated energy company. It produces, trades, transmits and supplies gas, electricity and heat. Eneco undertakes the sale, rental, installation, and maintenance of heating and hot water equipment; and maintenance of the electricity, gas and district heat ne …
  • Calavo Growers, Inc. (CVGW):企業の財務・戦略的SWOT分析
    Calavo Growers, Inc. (CVGW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Martin Midstream Partners L.P.:企業の戦略・SWOT・財務情報
    Martin Midstream Partners L.P. - Strategy, SWOT and Corporate Finance Report Summary Martin Midstream Partners L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • InspireMD Inc (NSPR):医療機器:M&Aディール及び事業提携情報
    Summary InspireMD Inc (InspireMD) is a medical device company that develops and commercializes embolic prevention systems and neurovascular devices. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for us …
  • GrafTech International Ltd:企業の戦略・SWOT・財務分析
    GrafTech International Ltd - Strategy, SWOT and Corporate Finance Report Summary GrafTech International Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • CUNA Mutual Group:企業の戦略・SWOT・財務情報
    CUNA Mutual Group - Strategy, SWOT and Corporate Finance Report Summary CUNA Mutual Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Ushdev International Limited (511736):企業の財務・戦略的SWOT分析
    Ushdev International Limited (511736) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • ConocoPhillips (COP)-石油・ガス分野:企業M&A・提携分析
    Summary ConocoPhillips is an independent upstream oil and gas company. The company explore for, produce, transport and market crude oil, bitumen, natural gas, liquefied natural gas (LNG) and natural gas liquids across the world. It has assets across North America, Europe, Asia and Australia. Its ass …
  • Snowy Hydro Ltd:企業の戦略的SWOT分析
    Snowy Hydro Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆